A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer (NCT02985957)

Summary

Patients eligible to participate in this study will receive Ipilimumab alone, Nivolumab and Ipilimumab, or Cabazitaxel and Prednisone.

This clinical trial is for patients who have metastatic castration resistant Prostate Cancer (mCPRC ) that has progressed while on Docetaxel. This trial is investigating the safety and effects (good or bad) of specific doses of Ipilimumab along with Nivolumab in patients with prostate cancer. Nivolumab and ipilimumab are investigational immunotherapies, which means that they are not currently approved to treat metastatic prostate cancer.  

This clinical trial’s objective is to find out whether Nivolumab, when combined with Ipilimumab, is safe and can slow down or stop the growth of mCPRC in patients who have progressed following prior Docetaxel treatment. Participation in this clinical trial is determined using a full eligibility criteria. Some key eligibility criteria are provided below.

You may be able to participate if:

• You have had a surgical/medical castration procedure.
• You have had ongoing androgen deprivation therapy or had surgical/medical castration, but your cancer has gotten worse or has not responded to the treatment you have been given.
• You have had bone problems and already receive medications to strengthen your bones.

• You have an infection or autoimmune disease.
• You have been diagnosed with cancer that has spread to your liver or brain.
• You have received pelvic radiotherapy, radiotherapy to bone marrow, and/or one-directed radiotherapy.
• You have received drug treatments that target T-cell activity.

Organization: Bristol-Myers Squibb (BMS)

If you are interested in this trial, review the following:

• ClinicalTrials.gov Identifier:NCT2985957
• For additional information go to Study Connect
• Use the “clinical trials glossary” and “dictionary” for words, phrases and treatments that you may not understand. 
• Register your interest or comments about this trial with PHEN

PHEN Contact: 617-481-4020

Please Note: This information is provided for educational and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor.